Pharvaris Posts €318M Cash, Nears Pivotal HAE Data Readout This Quarter
PHVS sits 69% above its 52-week low of $19.56.
Summary
Pharvaris reported Q2 2026 financials with €318 million in cash and a €47.8 million net loss. The company expects topline data from the pivotal CHAPTER-3 prophylaxis trial this quarter, a major catalyst for the deucrictibant franchise. The FDA accepted the NDA for the on-demand formulation with a PDUFA date of April 23, 2027, and the EMA validated the MAA in July. An Expanded Access Program has opened in the U.S., and enrollment continues in the long-term extension and AAE-C1INH studies. The cash runway extends into 2028, supporting pre-commercial activities and lifecycle management. This follows the July NDA acceptance and builds momentum toward a potential first approval.
At the time of this announcement, PHVS was trading at $33.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $19.56 to $36.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.